Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Investor Desk Presents US Highland, Inc. (OTC PINK: UHLN), a diversified product development, sales, and marketing company.
Since its founding in 1997 as Highland AB in Sweden, the Texas-based company has been developing and manufacturing high-performance single cylinder and V-twin powertrains used for a variety of applications. In September 2015, the publicly traded company began diversifying its operations, guiding startups in the marketing, reselling, and distributing of their products, as well as helping customers establish their brand and penetrate the U.S. market.
Overseeing the company’s growth is chief executive officer and president Josh Whitaker, a marketing executive with global experience in technology marketing, strategy, and implementation. Whitaker has worked with high-profile brands like Red Bull and Under Armour, as well as industry leading companies like Tucker Rocky Distributing and KTM Motorcycles.
Over the past two decades, US Highland, Inc. has tapped a variety of distribution channels, enabling growing businesses, both domestic and foreign, to launch their products in the United States whether wholesale, retail, or over the Internet.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7660851-us-highland-the-investor-desks-new-company/
Health conscious consumers who have struggled to meet their daily required servings of fruits and vegetables—and the vital nutrients that come with—have an easy solution for adding more vitamins to their diet with the introduction of Rader Farms’ Fruit PLUS Vitamins line of enriched berries, arriving in nearly 3,000 new stores across the U.S. this month.
Fruit PLUS Vitamins takes Rader Farms’ premium grade berries that are bursting with rich, sweet flavor and adds nutrients sourced from whole fruits and vegetables to boost vitamin levels by 25 percent, without impacting taste or texture. The end result is a revolutionary new line of frozen fruit that offers supremely delicious taste AND significantly higher nutritional value in a single, easy-to-implement method.*
Rader Farms’ new Fruit PLUS Vitamins has a suggested retail price of $3.49 - $3.99 per 12-ounce package. Frozen fruit lovers can try it now with a $1.00 off coupon and a chance to win a premium Ninja® blender here (http://woobox.com/2288k3). Additionally, a direct link to a downloadable coupon can be found here.
Consider the nutritional value of one cup of traditional unsweetened blueberries when compared to a similar serving of blueberries from Rader Farms’ Fruit PLUS Vitamins line below. It becomes easy to see how smoothie recipes, yogurt toppings and morning cereal rituals might come alive with a boost of nutrition.
To view the multimedia release go to:
http://www.multivu.com/players/English/7630251-rader-farms-fruit-plus-vitamins/
